Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Inventia

Drug and asset intelligence for Inventia with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
1
Stage
Development stage unavailable

Sponsor company

AstraZeneca →

Mechanism of action

SGLT2 Inhibitor

Recent signals(5)

RegulatoryAugust 19, 2026

ANDA201991 for Metformin Hydrochloride Approved by FDA

The FDA has approved the ANDA201991 application for Metformin Hydrochloride submitted by Inventia, classified under standard review priority.

RegulatoryAugust 17, 2026

FDA Approval Application for Dapagliflozin by Inventia

The FDA has received an approval application (ANDA211156) for Dapagliflozin from Inventia, classified as a standard review.

Regulatory
August 11, 2026

FDA grants AP status for Dapagliflozin ANDA211156 by Inventia

The FDA has granted approval status (AP) for the Abbreviated New Drug Application (ANDA) 211156 for Dapagliflozin submitted by Inventia.

RegulatoryJuly 21, 2026

FDA Accepts Supplement Application for Dapagliflozin by Inventia

The FDA has accepted the supplemental application for dapagliflozin submitted by Inventia.

RegulatoryJune 22, 2026

FDA Accepts Supplement Application for Dapagliflozin by Inventia

The FDA has accepted the supplemental application for dapagliflozin submitted by Inventia.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

AstraZeneca — Inventia

June 22, 2026 · N/A

Indications

Diabetes →

Therapeutic areas

Diabetes →
Diabetes · SGLT2 Inhibitor →
Oral Hypoglycemic →
SGLT2 Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.